Sudden cardiac death due to ?2-agonist therapy: Is a genetic basis overlooked?

Yalta K.Sivri N.Geyik B.Aksoy Y.Yetkin E.2024-06-122024-06-1220121995-1892https://hdl.handle.net/20.500.14551/17672[No abstract available]eninfo:eu-repo/semantics/closedAccessBeta 2 Adrenergic Receptor; Beta 2 Adrenergic Receptor Stimulating Agent; Fenoterol; Sotalol; Adrenergic Stimulation; Arrhythmogenesis; Cardiotoxicity; Catecholaminergic Polymorphic Ventricular Tachycardia; Channelopathy; Drug Fatality; Genetic Susceptibility; Heart Muscle Refractory Period; Human; Letter; Long Qt Syndrome; Pharmacogenetics; Qt Dispersion; Qt Prolongation; Sudden Death; Syncope; T Wave; Torsade Des Pointes; Adrenergic Beta-2 Receptor Agonists; Biomarkers, Pharmacological; Death, Sudden, Cardiac; Electrocardiography; Genetic Predisposition To Disease; Humans; Membrane Potentials; Polymorphism, Genetic; Prognosis; Receptors, Adrenergic, Beta; Signal TransductionSudden cardiac death due to ?2-agonist therapy: Is a genetic basis overlooked?Letter2322-s2.0-8485904741122447478Q3